CAPP, The Breast Test for Cancer, is Well Received in Argentina.

Business Editors & Health/Medical Writers

RENO, Nev.--(BUSINESS WIRE)--Feb. 8, 2001

Jim Holmes, CEO of Lifeline BioTechnologies, Inc., (NQB:LBTI) announced today that encouraging progress is being made in the company's clinical trials, which are ongoing in Argentina.

Holmes returned from there three days ago. He and William Reeves, the company's President and Founder, were inspecting results of the trials and discussing possible licensing arrangements for CAPP(TM), their early breast cancer detection system.

The retrospective phase of the trials is nearing completion. In this phase, the CAPP(TM) (Computer Assisted Physiological Profile) test was used on women who had already been screened and identified as having breast cancer. Professor Martin Laguens, M.D., Chief of Pathology at the University of La Plata School of Medicine and the head of Lifeline's clinical investigations in South America, noted that the results of the initial findings of these tests had confirmed 55 cancers. All the data gathered about these cases will be used to further train Chrononet(TM), Lifeline's patented and proprietary Artificial Neural Network Analysis computer system, and broaden its capability of detecting and differentiating many types of cancers.

The prospective segment of the clinical trials got underway in December 2000. An additional 350 women will be tested in this segment, and these will be women who have not previously been identified by any screening process as having any kind of breast cancer problem. The CAPP(TM) test will therefore be finding cancers not anticipated nor previously looked for, and identifying them at a much earlier stage than has heretofore been possible.

Reeves noted that meetings were held with representatives of the Hospital Employees Union, which had earlier expressed interest in having its women members receive the CAPP(TM) test. It has now been proposed that an initial group of 300 female Union members would be tested, commencing next month and to be completed by June 2001. (Note: This is entirely separate from the 350 mentioned above.) Assuming satisfactory results, an additional 2,700 women would then be tested. Ultimately, the prospect is that the test would be administered to all of the more than 30,000 Hospital Employees Union members, which includes hospital workers, nurses, doctors and doctors' wives.

Holmes also commented on the progress of a proposed strategic alliance, as previously reported by Lifeline. Meetings with a group of Argentinean businessmen have led to the prospect of licensing the group for the marketing of the CAPP(TM) test in South America, Central America and Mexico. Final details of the licensing agreement are being discussed and a formal agreement is probable in the near future.

Under the terms of any such licensing agreement, the manufacturing of the CAPP(TM) system will remain with Lifeline and all its components will be supplied by Lifeline to the Licensees. The analytical neural computer system (Chrononet(TM)) will also be retained by Lifeline and all testing will be submitted to it for interpretation. The results of the interpretation will be returned to the testing physician for his use in recommending therapy to his patient.

Similar in function to a PAP smear that has reduced cervical cancer deaths by 70% in the last two decades, CAPP(TM), the breast test, is programmed to take readings from its sixteen sensors, eight on each breast, every five minutes over a 48-hour test period. Upon completion, the data is downloaded to the Chrononet(TM) for interpretation. This results in a virtual real-time examination and provides, among many other things, a method of identifying breast cancer at a significantly earlier pathological stage than any other currently available diagnostic procedure.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to delays in testing and evaluation, completion of the clinical trials, positive results of the clinical trials, government approval, market acceptance of new technologies or products and other risks.